OpenAI acquires drug development platform Orchestra Bio, folding it into Rosalind as AI race moves into biotech

OpenAI has acquired Orchestra Bio, a drug development platform that helps biopharma teams coordinate studies with AI agents. The team and technology will be folded into Rosalind (including GPT-Rosalind and Rosalind Workbench), with the goal of getting new therapies to patients faster, according to Axios.

Detected & updated continuously · Source: Nebula